The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010–2014

@article{Brennan2017TheCM,
  title={The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010–2014},
  author={Michael Brennan and Rachel Tanner and Sheldon Morris and Thomas J. Scriba and Jacqueline M. Achkar and Andrea Zelmer and David A. Hokey and Angelo A. Izzo and Sally A Sharpe and Ann Williams and Adam Penn-Nicholson and Mzwandile Erasmus and Elena Stylianou and Daniel F. Hoft and Helen McShane and Helen A. Fletcher},
  journal={Clinical and Vaccine Immunology : CVI},
  year={2017},
  volume={24}
}
ABSTRACT The development of a functional biomarker assay in the tuberculosis (TB) field would be widely recognized as a major advance in efforts to develop and to test novel TB vaccine candidates efficiently. We present preliminary studies using mycobacterial growth inhibition assays (MGIAs) to detect Mycobacterium bovis BCG vaccine responses across species, and we extend this work to determine whether a standardized MGIA can be applied in characterizing new TB vaccines. The comparative MGIA… 
The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
TLDR
This approach aims to provide a method for high-throughput down-selection of vaccine candidates going forward to in vivo efficacy testing, thus expediting the development of a more efficacious TB vaccine and offering potential refinement and reduction to the use of NHPs for this purpose.
The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells.
TLDR
This approach aims to provide a method for high-throughput down-selection of vaccine candidates going forward to in vivo efficacy testing, thus expediting the development of a more efficacious TB vaccine and offering potential refinement and reduction to the use of NHPs for this purpose.
Assessment of the reproducibility and inter-site transferability of the murine direct splenocyte mycobacterial growth inhibition assay (MGIA)
Tuberculosis (TB) vaccine candidates must be tested for safety and efficacy using preclinical challenge models prior to advancement to human trials, because of the lack of a validated immune
Adaption of the ex vivo mycobacterial growth inhibition assay for use with murine lung cells
TLDR
An optimised ex vivo lung MGIA is presented to assess the ability of host cells within the lung to inhibit mycobacterial growth, including Bacille Calmette–Guérin (BCG) and Mycobacterium tuberculosis (MTB) Erdman.
RUTI Vaccination Enhances Inhibition of Mycobacterial Growth ex vivo and Induces a Shift of Monocyte Phenotype in Mice
TLDR
A novel mechanism of action of the RUTI vaccine is demonstrated, which suggests the importance of a balanced M1/M2 monocyte function in controlling mycobacterial infection and may aid the development of therapeutic vaccination regimens for TB in the near future.
Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
TLDR
This data demonstrate that the direct MGIA using peripheral blood mononuclear cells (PBMC) is measuring a biologically relevant response that correlates with protection from in vivo human BCG infection across two independent cohorts, the first report of an MGIA correlating with in vivo protection in the species-of-interest, humans, and furthermore on a per-individual as well as per-group basis.
Evaluation of Tuberculosis Vaccine Candidate, pcDNA3.1-rpfD using Mycobacterial Growth Inhibition Assay (MGIA)
TLDR
Results suggest that pcDNA3.1-rpfD may be effective in controlling tuberculosis growth and may provide a clue for the development of the tuberculosis vaccine.
In vitro Mycobacterial Growth Inhibition in South Korean Adults With Latent TB Infection
TLDR
The Mtb infection status had a significant impact on mycobacterial growth inhibition in PBMC from healthy adults in South Korea, a country with an intermediate burden of tuberculosis, with healthy controls showing the greatest myc Cobacterium tuberculosis growth inhibition.
Current approaches toward identifying a correlate of immune protection from tuberculosis
TLDR
The identification of COP would allow the rational design and development of vaccine candidates which can then be optimized and prioritized based on the induction of these immune responses, once validated in field efficacy trials.
...
...

References

SHOWING 1-10 OF 37 REFERENCES
Development of a Murine Mycobacterial Growth Inhibition Assay for Evaluating Vaccines against Mycobacterium tuberculosis
TLDR
An in vitro functional assay for evaluating TB vaccines that directly assesses the capacity of immune splenocytes to control the growth of Mycobacterium tuberculosis within infected macrophages is developed and correlated with the protective immune responses detected in vivo at 28 days postchallenge in a mouse model of pulmonary tuberculosis.
Novel Human In Vitro System for Evaluating Antimycobacterial Vaccines
TLDR
The whole-blood luminescence model detects changes in cellular immune responses to mycobacteria induced by BCG vaccination, a useful new tool in studying the immunogenicity of newly developed vaccine candidates prior to large field trials assessing efficacy.
Ex vivo mycobacterial growth inhibition assay (MGIA) for tuberculosis vaccine testing - a protocol for mouse splenocytes
TLDR
A detailed protocol for an ex vivo MGIA in mouse splenocytes is described, to facilitate technology transfer and reproducibility between laboratories and to serve as a novel tool to facilitate vaccine testing.
A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis
TLDR
The ex vivo mycobacterial growth inhibition assay could be a useful tool to help assess vaccine efficacy in future, alongside other established methods, and could also be a valuable tool for determination of underlying immune mechanisms.
Inhibition of Mycobacterial Growth In Vitro following Primary but Not Secondary Vaccination with Mycobacterium bovis BCG
TLDR
This is the first study to demonstrate that an in vitro growth inhibition assay can identify a difference in vaccine responses by comparing both primary and secondary BCG vaccinations, suggesting that in vitrogrowth inhibition assays may serve as better surrogates of clinical efficacy than the assays currently used for the assessment of candidate TB vaccines.
Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine
TLDR
C capsular polysaccharide conjugates are developed by linking mycobacterial capsular arabinomannan (AM) to either Mtb Ag85b or B. anthracis protective antigen (PA) and studied their immunogenicity by ELISA and AM glycan microarrays and protection efficacy in mice.
Bactericidal Activity in Whole Blood as a Potential Surrogate Marker of Immunity after Vaccination against Tuberculosis
TLDR
The balance between immunity and virulence in a whole blood infection model in which intracellular mycobacterial survival was measured using BACTEC indicates that whole blood culture may be used to measure immunity to M. tuberculosis.
...
...